Close Menu
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
What's Hot

A new molecular model of bilayer graphene with higher semiconducting properties

May 31, 2025

5 Nanomaterial Innovations That Didn’t Deliver (Yet)

May 30, 2025

Scientists identify new 2D copper boride material with unique atomic structure

May 30, 2025
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
  • News
  • Medical
  • Technology
  • Nanomaterials
  • Research
  • Blog
    • Nasiol.com
  • Contact
    • Tech7685@gmail.com
Facebook X (Twitter) Instagram
Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily Nanotech – Nanomaterials | Medical | Research | News Stories Updated Daily
Home»News»Drug-delivering aptamers target leukemia stem cells for a one-two knockout punch
News

Drug-delivering aptamers target leukemia stem cells for a one-two knockout punch

April 15, 2025No Comments4 Mins Read
Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
Drug-delivering aptamers target leukemia stem cells for a one-two knockout punch
Share
Facebook Twitter LinkedIn Pinterest Telegram Email
A graphic showing, top to bottom, how DNA aptamers target two specific markers on a leukemia stem cell’s surface, enter the cell and deliver anticancer drugs, resulting in death of the cancer cell. Credit: Abhisek Dwivedy

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

The aptamers—short single-strand snippets of DNA that can target molecules like larger antibodies do—not only deliver cancer-fighting drugs, but also are themselves toxic to the cancer stem cells, the researchers said.

Led by Xing Wang, a U. of I. professor of bioengineering and of chemistry, the researchers documented their findings in the journal Advanced Functional Materials.

“This work demonstrates a way to get to the root of leukemia,” Wang said. “Targeted cancer treatments often have problems with toxicity or efficacy. Our aptamers seek out these stem cells specifically and kill them effectively.”

Leukemia and other cancers of the blood are more difficult to target than cancers that produce localized tumors because the cancerous cells circulate throughout the body and can’t be surgically removed, said postdoctoral researcher Abhisek Dwivedy, first author of the paper.

Leukemia has a high rate of relapse due to its evasive stem cells. Though they make up a tiny fraction of cancerous cells, leukemia stem cells have the ability to evade chemotherapy by retreating to the bone marrow, since they share markers and properties, Dwivedy said. The cancerous cells can lurk, sometimes for years, and later proliferate and migrate.

“It’s important in leukemia, lymphoma or other blood cancers that we actually target and eliminate these stem cells, because as long as any are remaining, they can cause relapse and secondary cancers,” Dwivedy said.

See also  Vortex electric field discovery could impact quantum computing

The researchers began by finding DNA aptamers that seek out markers found on the surface of acute myeloid leukemia stem cells. They wanted to target not just the cancer, but the stem cells specifically.

“A big thing we showed in this study is that having two targets is better than one in terms of selectivity,” Wang said. “There are known antibody-drug conjugates for blood cancers that target one marker, but that marker is also found on a lot of healthy cells. So there is a lot of toxicity associated with antibody conjugates. But we used two targets: a combination often found in leukemia cancer cells and leukemia stem cells. The two together give a very specific target.”

The researchers then paired their aptamers with the leukemia-fighting drug daunorubicin. The drug-laden aptamers carry the drug to their target, then release the drug once inside the cell so the drug can act.

“This is especially important for drugs like daunorubicin, because the drug on its own cannot cross the cell membrane easily. But aptamers can carry it in,” Dwivedy said.

The researchers tested the drug-delivering aptamers in leukemia cell cultures as well as in live mice with leukemia.

Discover the latest in science, tech, and space with over 100,000 subscribers who rely on Phys.org for daily insights.
Sign up for our free newsletter and get updates on breakthroughs,
innovations, and research that matter—daily or weekly.

After 72 hours, the aptamer alone had reduced the cancer cells in culture by 40%, demonstrating the aptamer’s toxicity to the cancer, the researchers report. When the aptamers carried the leukemia-fighting drug, the cells were wiped out with a dose 500 times smaller than the standard dosage of the drug. In mice with leukemia, delivering the drug via aptamer yielded the same efficacy at a dose 10 times smaller than the clinical standard, showing that the one-two punch of the aptamer and drug is more effective than either alone.

See also  Mesoporous MoS₂ strategy boosts efficiency and stability of perovskite solar cells

“This was exciting to us, because in cancer research, what we see in vitro is not always what we see in the body. Yet we saw excellent survivability and tumor reduction in the mice treated with our aptamer-drug conjugates, at one-tenth of the therapeutic dose, and no off-target effects,” Wang said.

The researchers said they hope to expand their suite of drug-delivering aptamers by identifying key marker combinations for other cancers, as well as coupling the aptamers with other drugs.

“Every cancer cell has a signature in its surface biomarkers. If we can find markers that are present uniquely in cancer cells, we can target other cancer types as well. Also, in my experience, it’s much easier to pair a drug with the DNA molecules than proteins, so that opens possibilities for delivering more drugs this way,” Dwivedy said.

University of Illinois at Urbana-Champaign



Source link

aptamers cells Drugdelivering knockout leukemia onetwo punch Stem target
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

A new molecular model of bilayer graphene with higher semiconducting properties

May 31, 2025

5 Nanomaterial Innovations That Didn’t Deliver (Yet)

May 30, 2025

Scientists identify new 2D copper boride material with unique atomic structure

May 30, 2025

Nanoscale biosensor lets scientists monitor molecules in real time

May 30, 2025

How should we govern nanotechnology?

May 29, 2025

The Future of Needle-Free Immunization

May 28, 2025

Comments are closed.

Top Articles
News

Microscopy method overcomes the traditional resolution limit for the fast co-tracking of molecules

News

Catching steroid hormones with nanotubes

News

UV Tape That Transfers Wonder Materials Without the Hassle

Editors Picks

A new molecular model of bilayer graphene with higher semiconducting properties

May 31, 2025

5 Nanomaterial Innovations That Didn’t Deliver (Yet)

May 30, 2025

Scientists identify new 2D copper boride material with unique atomic structure

May 30, 2025

New contact lenses allow wearers to see in the near-infrared

May 30, 2025
About Us
About Us

Your go-to source for the latest nanotechnology breakthroughs. Explore innovations, applications, and implications shaping the future at the molecular level. Stay informed, embrace the nano-revolution.

We're accepting new partnerships right now.

Facebook X (Twitter) Instagram Pinterest
Our Picks

Researchers realize controlled synthesis of Au-Ag heterodimer arrays for high-resolution encrypted information

June 2, 2024

Study shows how organic molecules impact gold nanoparticles’ electrochemical properties

July 24, 2024

A New Method for Non-invasive or Inline Detection of Aggregates and Oversized Particles in Nanosuspensions

October 3, 2024

Subscribe to Updates

Get the latest creative Nano Tech news from Elnano.com

© 2025 Elnano.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.

Cleantalk Pixel